Osheru receives funding to advance Ziplyft device for blepharoplasty surgery

(Image Credit: AdobeStock)

The International Society of Aesthetic Plastic Surgery (ISAPS) found an estimated 1.7 million eyelid surgeries were performed globally in 2023, a 24% increase compared to 2022. Out of these procedures, blepharoplasty, a procedure aimed at rejuvenating the appearance of the eyelids, is still one of the most sought-after cosmetic surgeries in the US. With a demand for safer, less invasive alternatives, companies have been working to make the procedure more accessible and painless.

Osheru, a medical device company specializing in innovative solutions for skin surgery, announced the successful completion of a $4.7 million funding round to further expand the development and commercialization of Ziplyft. The device is designed to address the challenges linked to traditional blepharoplasty procedures, including extended recovery times and risk of complications like wound dehiscence and asymmetry. Ziplyft ensures reduced downtime and enhanced aesthetic outcomes for patients through its proprietary design.

The funding was led by an investment from Nike co-founder Phil Knight, as well as from the Oregon ToughTech BreakThrough Fund managed by ONAMI for Business Oregon. SOPHINCAP, the Corporate Venture Fund of Laboratorios Sophia, an international ophthalmology company, also contributed to advancing the device.

“This $4.7 million funding marks a pivotal moment for Osheru,” said Patricia Buehler, MD, CEO. “It demonstrates the strong confidence in Ziplyft from both the medical community and investors, validating our vision to revolutionize blepharoplasty with cutting-edge technology.”

With commercialization aimed for next year, Osheru is set to introduce Ziplyft as a new solution for ophthalmologists, oculoplastic surgeons, and facial plastic surgeons looking to optimize patient outcomes in eyelid surgery.

“Despite the challenging fundraising environment for startups today, Osheru’s success in securing this funding round highlights their perseverance and the compelling value proposition of Ziplyft,” Skip Rung, ONAMI president, said. “We are enthusiastic, about the potential of the technology to positively impact patient outcomes.”

Reference:

1. Osheru Secures $4.7 Million Seed Funding to Advance Revolutionary Ziplyft Device for Blepharoplasty Surgery. News release. Business Wire. Accessed July 24, 2024. Osheru Secures $4.7 Million Seed Funding to Advance Revolutionary Ziplyft Device for Blepharoplasty Surgery | Business Wire